Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19-Reply.
Publication
, Journal Article
McCarthy, MW; Lindsell, CJ; Naggie, S
Published in: JAMA
May 16, 2023
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
May 16, 2023
Volume
329
Issue
19
Start / End Page
1702 / 1703
Location
United States
Related Subject Headings
- Time Factors
- Recovery of Function
- Humans
- General & Internal Medicine
- Fluvoxamine
- Double-Blind Method
- COVID-19 Drug Treatment
- COVID-19
- Antiviral Agents
- 42 Health sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
McCarthy, M. W., Lindsell, C. J., & Naggie, S. (2023). Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19-Reply. JAMA, 329(19), 1702–1703. https://doi.org/10.1001/jama.2023.5064
McCarthy, Matthew W., Christopher J. Lindsell, and Susanna Naggie. “Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19-Reply.” JAMA 329, no. 19 (May 16, 2023): 1702–3. https://doi.org/10.1001/jama.2023.5064.
McCarthy MW, Lindsell CJ, Naggie S. Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19-Reply. JAMA. 2023 May 16;329(19):1702–3.
McCarthy, Matthew W., et al. “Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19-Reply.” JAMA, vol. 329, no. 19, May 2023, pp. 1702–03. Pubmed, doi:10.1001/jama.2023.5064.
McCarthy MW, Lindsell CJ, Naggie S. Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19-Reply. JAMA. 2023 May 16;329(19):1702–1703.
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
May 16, 2023
Volume
329
Issue
19
Start / End Page
1702 / 1703
Location
United States
Related Subject Headings
- Time Factors
- Recovery of Function
- Humans
- General & Internal Medicine
- Fluvoxamine
- Double-Blind Method
- COVID-19 Drug Treatment
- COVID-19
- Antiviral Agents
- 42 Health sciences